John M. Evans Beam Therapeutics Inc. (BEAM) insider trading activity

John M. Evans is CEO of Beam Therapeutics Inc.. Currently has a direct ownership of 986,667 shares of BEAM, which is worth approximately $23.9 Million. The most recent transaction as insider was on Oct 02, 2025, when has been sold 25,000 shares (Common Stock) at a price of $24.63 per share, resulting in proceeds of $615,750. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 987K

0.04% 3M change

5.11% 12M change

Total Value Held $23.9 Million

John M. Evans Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 02 2025	SELL Open market or private sale	$615,750 $24.63 p/Share	25,000 Reduced 2.47%	986,667 Common Stock
Oct 02 2025	BUY Exercise of conversion of derivative security	$16,750 $0.67 p/Share	25,000 Added 2.41%	1,011,667 Common Stock
Oct 01 2025	SELL Open market or private sale	$612,750 $24.51 p/Share	25,000 Reduced 2.47%	986,667 Common Stock
Oct 01 2025	BUY Exercise of conversion of derivative security	$16,750 $0.67 p/Share	25,000 Added 2.41%	1,011,667 Common Stock
Apr 01 2025	SELL Open market or private sale	$562,666 $18.35 p/Share	30,663 Reduced 3.02%	986,249 Common Stock
Mar 31 2025	BUY Grant, award, or other acquisition	-	77,500 Added 7.09%	1,016,159 Common Stock
Jan 30 2025	SELL Open market or private sale	$810,600 $27.02 p/Share	30,000 Reduced 3.2%	908,659 Common Stock
Sep 30 2024	SELL Open market or private sale	$1,476,000 $24.6 p/Share	60,000 Reduced 6.01%	938,659 Common Stock
Jun 27 2024	SELL Open market or private sale	$1,470,000 $24.5 p/Share	60,000 Reduced 5.67%	998,343 Common Stock
Apr 01 2024	SELL Open market or private sale	$581,617 $32.13 p/Share	18,102 Reduced 1.68%	1,058,343 Common Stock
Mar 31 2024	BUY Grant, award, or other acquisition	-	77,500 Added 6.72%	1,076,445 Common Stock
Mar 28 2024	SELL Open market or private sale	$2,031,600 $33.86 p/Share	60,000 Reduced 5.67%	998,262 Common Stock
Jan 31 2024	SELL Open market or private sale	$1,519,800 $25.33 p/Share	60,000 Reduced 5.37%	1,058,262 Common Stock
Apr 04 2023	SELL Open market or private sale	$188,881 $29.09 p/Share	6,493 Reduced 0.58%	1,117,979 Common Stock
Apr 03 2023	SELL Open market or private sale	$156,429 $30.31 p/Share	5,161 Reduced 0.46%	1,124,472 Common Stock
Mar 31 2023	BUY Exercise of conversion of derivative security	$99,997 $7.22 p/Share	13,850 Added 1.21%	1,129,153 Common Stock
Mar 31 2023	BUY Grant, award, or other acquisition	-	56,250 Added 4.8%	1,115,303 Common Stock
Mar 06 2023	BUY Small Acquisition	-	225 Added 0.02%	1,059,053 Common Stock
Oct 31 2022	SELL Open market or private sale	$1,394,100 $46.47 p/Share	30,000 Reduced 2.76%	1,058,520 Common Stock
Jul 28 2022	SELL Open market or private sale	$2,002,200 $66.74 p/Share	30,000 Reduced 2.68%	1,088,520 Common Stock
Apr 28 2022	SELL Open market or private sale	$1,155,600 $38.52 p/Share	30,000 Reduced 2.61%	1,118,520 Common Stock
Apr 28 2022	BUY Exercise of conversion of derivative security	$245,529 $4.13 p/Share	59,450 Added 4.92%	1,148,520 Common Stock
Mar 31 2022	SELL Open market or private sale	$370,088 $59.11 p/Share	6,261 Reduced 0.57%	1,089,070 Common Stock
Mar 31 2022	BUY Grant, award, or other acquisition	-	56,250 Added 4.88%	1,095,331 Common Stock
Oct 06 2021	SELL Open market or private sale	$2,325,692 $83.96 p/Share	27,700 Reduced 2.61%	1,033,525 Common Stock

Also insider at

VERV

Verve Therapeutics, Inc. Healthcare

Director

JME

John M. Evans

CEO

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BEAM shares.

Notify only if

Value

Insider Trading

Get notified when an Beam Therapeutics Inc. insider buys or sells BEAM shares.

Notify only if

Operation

Value

Type

News

Receive news related to Beam Therapeutics Inc.

Track Activities on BEAM

Account